| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. Publisher’s Note: In preparation for the new GDPR taking effect this month, we would like to reconfirm your subscription to our newsletter(s). Please click this link to reconfirm your subscription. For more information about GDPR, please visit this page. | |
|
Featured Story | | | Tuesday, May 22, 2018 Former Novartis CEO Joe Jimenez—who authorized the ill-fated Michael Cohen deal—was set to join the board of a leading hedge fund, but the plans are now on hold, according to the Wall Street Journal. |
|
|
| This week's sponsor is FierceBiotech Executive Breakfast at BIO 2018. | |  | |
Top Stories Of The Week Wednesday, May 23, 2018 AstraZeneca has officially opened its new research facility in South San Francisco, bundling five of its Bay Area sites into a single unit at the heart of California’s biotech cluster. Wednesday, May 23, 2018 Merck already controls a big piece of the first-line non-small cell lung cancer market, and it likely just secured most of the rest. Its immunotherapy Keytruda nailed a study in previously untreated patients with the squamous form of the disease, who represent up to 30% of newly diagnosed NSCLC cases. Thursday, May 24, 2018 Armed with a trio of partnerships and $260 million in the bank, Brii Biosciences' mission is to overcome the challenges that have prevented the spread of innovative medicines throughout China. Wednesday, May 23, 2018 AveXis, the gene therapy biotech Novartis snapped up for $8.7 billion, will build a new manufacturing plant in North Carolina to produce its specialized therapies. Tuesday, May 22, 2018 With Pfizer’s Xeljanz snapping up new indications and AbbVie’s upadacitinib on the way, makers of anti-inflammatory drugs will soon feel the heat from JAK inhibitors if they haven't already. But some will feel it more than others, Bernstein analysts say. Wednesday, May 23, 2018 The FDA issued a Class I recall for Abbott’s HeartMate 3 left ventricular assist device due to possible twisting of the outflow graft that could result in a persistent low-flow alarm, which normally signals potential safety risks including low blood flow or clotting that could lead to serious injury or death. Monday, May 21, 2018 Scientists engaged in the fight against obesity have long been aware that white fat cells burn energy and protect against obesity. But efforts to understand how white fat becomes “beige” and takes on all the good characteristics of brown fat have largely failed. Now researchers at American University believe they’ve uncovered a signaling pathway that prompts beige cells to burn energy. Wednesday, May 23, 2018 Pfizer is counting on several mid- and late-stage vaccine candidates to carry the torch after its megablockbuster pneumococcal shot Prevnar 13, the world's bestselling vaccine, slows down. But it's stocking its early pipeline, too. Wednesday, May 23, 2018 Pharmaceutical Product Development, along with its real-world business unit, Evidera, will represent the first contract research organization to join the Massachusetts Institute of Technology’s collaborative biotech think tank. Resources Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
